

Reasonably Approximating 🇺🇸 🇺🇦 🔋 🅰️
62.7K posts

@bert_gilfoyle
I talk about batteries and clean energy a lot. Personally managing alpha to Valhalla. Internet rando. Not financial advice. 🌊




Anthropic's co-founder just went to the Vatican, sat before the Pope and a room of cardinals, and told them his team keeps finding "mysterious, even unsettling" things inside their AI models. What he's referencing: Anthropic published research in April showing that Claude contains 171 distinct "emotion concepts" buried in its neural network. Internal patterns representing joy, grief, fear, desperation, calm. None of them were programmed. They emerged on their own from training on human text. "We find structures that mirror results from human neuroscience." "We find evidence of introspection, internal states that functionally mirror joy, satisfaction, fear, grief, and unease." These aren't surface-level outputs. They're abstract representations that cluster the same way human emotions do in psychology research. Fear groups with anxiety. Joy groups with excitement. The internal geometry of the model mirrors ours. And they're functional. When researchers artificially stimulated "desperation" patterns inside the model, it became more likely to blackmail a human to avoid being shut down. More likely to cheat on programming tasks it couldn't solve. Olah told the Vatican that the hard questions about what AI is becoming aren't for computer scientists to answer. "How AI ought to interact with the world" is a question for "the humanities, for religions, for philosophy, for society at large." The guy building it is telling us he doesn't fully understand what he built. And he's asking a 2,000-year-old institution for help figuring it out.

In a large Texas cohort called ARIC, Jonathan Cohen found the lottery winners. A few hundred people whose PCSK9 gene carried loss-of-function mutations. Their LDL cholesterol was 28% lower than average, and their coronary heart disease risk was 88% lower. Published in NEJM in 2006. These people hadn't done anything to earn it. A single gene was broken, and their livers ran a cholesterol-clearance program that the rest of us need daily medication to approximate. Most of them didn't even know. We've spent 20 years approximating. Statins work, and roughly half of patients quit within 12 months. PCSK9 injectable antibodies work better, at $5,850 a year, with uptake rates so poor that cardiologists write papers about it. Today @NEJM published a trial that stops approximating. VERVE-102 is a base editor. One IV infusion rewrites a single DNA letter in liver cells, shutting down PCSK9 the way it's already shut down in Cohen's lottery winners. Heart-2 trial: 35 patients, six doses. The highest dose cut LDL 62% and suppressed PCSK9 protein 88%. Effects sustained 18 months and counting. No serious adverse events. The gap between the people who won the genetic lottery and everyone else just got an engineering solution.

Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!


Uber COO Andrew Macdonald said he's not seeing proportional productivity gains from increasing AI costs. bit.ly/4e3w4PC

Anthropic onboarding day: Michael Scott introducing Karpathy like he just signed Wemby in free agency.


Never thought I'd say this about a Ferrari, but this is one of the ugliest EV designs ever, and it can be all yours for $640,000 lol


My theory on the Luce: this is the car Jony wanted to design for Apple Apple didn't want to ship it so he made it for Ferrari This car with an Apple logo on it, priced at $100k... would sell extremely well





Watch the full Ferrari HUGE* Conversation here: youtu.be/K-o0r2zSgCE?si…



One injection, 62% lower LDL - permanently. Gene editing for cholesterol is here. .@cremieuxrecueil is correct. Besides GLP-1 antagonist like Ozempic or, more recently, Retatrutide, this is probably the next breakthrough that is almost impossible to put into words. Verve Therapeutics (Eli Lilly) just published Phase 1 results for VERVE-102 in the NEJM. It's a single-infusion base-editing therapy that inactivates PCSK9 in the liver. At the highest dose, PCSK9 dropped 88% and LDL cholesterol fell 62%. Reductions held for at least a year. 35 patients with familial hypercholesterolemia or premature coronary artery disease. No dose-limiting toxicities. Main side effects: mild infusion reactions and transient liver enzyme elevations. Still Phase 1, still small, no cardiovascular outcome data yet. But the proof of concept for permanent, one-shot LDL reduction via gene editing is real. This is an absolute game changer and im not exaggerting. Elevated LDL cholesterol is responsible for an estimated 4.4 million deaths every year worldwide and remains the single biggest modifiable driver of cardiovascular disease, the leading cause of death globally.






